Showing results (271-280 of 415) with videos related to

Sort By:
Pageof 42
The American Journal of Emergency Medicine|January 1, 1990
Emergency cardiopulmonary bypass for resuscitation from prolonged cardiac arrestP Safar, N S Abramson, M Angelos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 23, 2011
Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysisJ A Barnes, A S Lacasce, Y Feng, et al.
Annals of Emergency Medicine|June 1, 1988
Predictors of electromechanical dissociation during cardiac arrestK Sutton-Tyrrell, N S Abramson, P Safar, et al.
Leukemia & Lymphoma|January 31, 2024
Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphomaMatthew M Lei, Mark N Sorial, Uvette Lou, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|June 5, 2003
Variability in serotonin and enterochromaffin cells in patients with colonic inertia and idiopathic diarrhoea as compared to normal controlsM. K. Baig, R. H. Zhao, S. L. Woodhouse, et al.
Leukemia & Lymphoma|July 25, 2025
Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphomaJeremy S Abramson, Manali Kamdar, Fei Fei Liu, et al.
Vaccine|October 3, 2012
Translating vaccine policy into action: a report from the Bill & Melinda Gates Foundation Consultation on the prevention of maternal and early infant influenza in resource-limited settingsJustin R Ortiz, Kathleen M Neuzil, Vincent I Ahonkhai, et al.
Molecular Cancer Therapeutics|January 3, 2023
Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene MaraleucelN Eric Olson, Seamus P Ragan, David J Reiss, et al.
Blood Advances|March 15, 2021
Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trialJeremy S Abramson, Tanya Siddiqi, Jacob Garcia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)Scott J Rodig, Jeremy S Abramson, Geraldine S Pinkus, et al.
Pageof 42